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ABSTRACT
 
  ىلع )GBP(  ينتنباباج راقع يقلت راثآ مييقتب انمق  :فادهلاا
 . لماولحا نارئفلا ةنجأ
  للاخ ةيبطلا مولعلل دناجرب ةعماجب ةساردلا ءارجإ تم  :ةقيرطلا
 ايئاوشعBalb/c  عون لماح ةرأف 30  ددع ميسقت تم .2008 ماع
 ةبرجتلا  اتعومجم  امهو  ينتعومجم  :تاعومجم  ثلاث  ىلا
 مجلم  50رادقمو  )ىلولأا  ةعومجملل(  مجلم  25رادقم  اتقلتو
 قافصلا  ربع )GBP(  ينتنباباج راقع نم )ةيناثلا  ةعومجملل(
 ةعومجم  تقلتو   .لملحا  نم  ىلولأا  اموي  رشع  ةسملخا  للاخ
 مايقلا تم  .يداعلا يحللما لوللمحا مكحتلا ةعومجم يهو ةدحاو
 لكيهلل ةجودزلما ةغبصلاو ةنجلأل اموي 18  ةدلم ةيجرالخا ةبقارلماب
 .يمظعلا
 يتلاو ةهباشم تابارطضا ةبرجتلا يتعومجم ىلع رهظ  :جئاتنلا
 يننلجا  مسج  نزو  يف  ضافخنا  )1  :يلاتلاك  اهفينصت  نكيم
 ةيلكيه تاهوشت )3  ،يرهجم هوشت )2  ،فاشترلاا يف ةدايزو
 ةبرجتلا  يتعومجم ىدل فاشترلااو مسلجا نزو ناك  .ةيمظع
 ىلع  مكحتلا  ةعومجم  عم  ةنراقم  ىلعأو  ظوحلم  لكشب  لقأ
 بويع ،غامدلا ةينارب ىلع ةيرهجلما تاهوشتلا تلمش  .يلاوتلا
 رخأت  عم  ةنجلأاو  يرقفلا  دومعلا  هوشت  و  كفلا  رصق  ،فارطلأا
  ،فنلجا ,مظعتلا  رخأت ىلع ةيمظعلا تاهوشتلا تلمتشا  .ومنلا
 .يكفلا جسنتلا صقنو فحقلا هوشت
 تاهوشت ريثي دق )GBP(  راقع نأ ةساردلا هذه تفشك  :ةتماخ
 للاخ  ارامتساب  هلامعتسا  تم  اذإ  ةروكذم  ريغو  ةقبسم  ةديدش
 ءاضعلأا نوكت و يبصعلا نوكتلا ،ةضيبلا عرز وأ سرغ لحارم
 لامعتسا للاخ ديدشلا رذلحا ذخأ حرتقلما نم كلذل  .لملحا نم
  مايقلا  متي  ىتح  لملحا  نم  ةركبلما  لحارلما  ءانثأ )GBP(  راقع
 .لضفأ لكشب راثلآا هذه مهفتل تاساردلا نم ديزلماب
ً
ً
ً
Objectives: To evaluate the effects of gabapentin 
)GBP( administration on mice fetuses. 
Methods: This study was carried out in Birjand 
University of Medical Sciences during 2008. Thirty 
Balb/c pregnant mice were divided randomly into 3 
groups: 2 experimental groups that received 25 mg/kg 
)I( and 50 mg/kg )II( of GBP intraperitoneally for 
the first 15 days of pregnancy, and a control group
that received normal saline. External observations 
of day 18 fetuses and skeleton double staining were 
performed. 
Results: Both experimental groups showed similar 
disorders that can be categorized as the following: 
1( decrease of fetal body weight and increase of 
fetal resorption, 2( macroscopic malformations, 
and 3( skeletal malformations. Fetal body weights 
were significantly lower, and fetus resorptions were 
significantly higher in both treated groups compared 
to the control group. Macroscopic malformations 
included exencephaly, limbs defects, brachygnathia, 
vertebral column deformity, and fetuses with severe 
retarded growth. Skeletal malformations included 
delayed ossification, scoliosis, calvaria deformity, and 
mandibular hypoplasia. 
Conclusion: This study revealed that GBP can induce 
previously unreported severe malformations if it is used 
continuously during the implantation, neurulation, 
and organogenesis stages of pregnancy. Therefore, it 
is suggested that great caution should be exercised in 
using GBP during the early stages of pregnancy until 
further studies are performed to better understand 
these effects. 
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Epilepsy is the second leading cause of CNS morbidity after cerebrovascular accidents,1 and 
approximately 1% percent of adults, and 5% of 
children are affected worldwide, and nearly all have to 
take antiepileptic drugs )AEDs(.2 The use of AEDs in 
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pregnancy may have potential effects on embryogenesis, 
neurological development, growth, and subsequent 
pediatric progress.2 Gabapentin )GBP(, with the trade 
name Neurontin, is a new anticonvulsant drug that 
was introduced by Park Davis Company in 1993 and 
approved by the US Food and Drug Administration 
for epilepsy.3 This AED is indicated for adjunctive use 
in individuals older than 12 years for the treatment of 
partial seizures, with or without becoming secondarily 
generalized.4,5 In addition to its use in the therapy 
of epilepsy, this drug is administered for relief of 
neuropathic pain and prophylaxis of migraine.4-8 Lack 
of appreciable metabolism, no drug interaction, rapid 
glomerular filtration rate, and good tolerance of this 
drug are reasons for its extensive usage.9 Low molecular 
weight )171D( and no binding to the plasma proteins 
are the probable causes of passing across the placental 
membrane.10 Ohman et al11studied the pharmacokinetics 
of GBP during delivery, lactation, and in the neonatal 
period, and reported an active transplacental transport 
of GBP, with accumulation in the fetus as an important 
consequence. However, despite expanding data on 
the usage of GBP, there is little information on its 
teratogenic effects. The first studies did not report 
any significant teratogenic effects of this drug on 
rodents.12,13 Some studies on rodents have shown that 
oral consumption of this drug )1000-3000 mg/Kg per 
day( causes delayed ossification of several bones in the 
skull, vertebral column, upper, and lower limbs during 
the organogenesis period.13 Another report has shown 
that consumption of GBP during pregnancy can cause 
hydronephrosis and hydroureter in rat fetuses.3,13 One 
case of a more severe malformation, holoprosencephaly, 
following consumption of GBP, and carbamazepine in 
humans has been reported.14 In a previous study,15 we 
reported that intraperitoneal injection of GBP )1400­
1800 mg/day( in pregnant Balb/C mice lead to severe 
malformations, such as neural tube defects )NTD(, and 
limb deformities during gastrulation and neurulation 
)G1-G10(. Montouris’ study16 on human fetuses showed 
that GBP exposure during pregnancy was not associated 
with an increased risk for adverse maternal and fetal 
events, and Crawford17 suggested that the 2 newer AEDs 
)GBP and Lamotrigine( appear to be less harmful to the 
fetuses when compared to the rest. Therefore, in this 
study, the teratogenic effects of GBA administration 
at 2 doses during implantation, neurulation, and the 
organogenesis stages of pregnancy have been evaluated. 
Accordingly, the objectives of the present study were: 1(
evaluate GBP-induced murine fetotoxicity at different 
dose levels )25-50 mg/kg(, on fetal body weight, and 
fetal resorption; 2( describe the gross malformations 
that occur after GBP administration with the above 
dosage levels; and 3( assess the teratogenic effects of 
GBP on the skeletal system using Alizarin red S-Alcian 
blue double staining. 
Methods. This study was carried out in Birjand 
University of Medical Sciences during 2008. Virgin 
female Balb/c mice, weighing 28-30 gram )8-9 weeks 
old( were used in this experimental study. The animals 
were maintained in a climate-controlled room under 
a 12-hour alternating light/dark cycle )9.00-21.00 h 
light(, 20.1-21.20C temperatures, and 50-55.5% relative 
humidity. Dry food pellets and water were provided ad 
libitum. After 2 weeks of acclimation to the diet and 
the environment, 2 females were caged with a male 
of the same strain overnight. The presence of vaginal 
plug the following morning confirmed that mating 
had taken place and was designated as Gestation Day 
0 )GD0(. Maternal weights were measured throughout 
the experiment. The approval for this study was gained 
from the Birjand University of Medical Sciences Animal 
Care and Ethics Committee. Thirty pregnant mice were 
randomly divided into 3 groups: 2 experimental groups 
that received 25 mg/kg )I( and 50 mg/kg )II( of GBP 
intraperitoneally for the first 15 days of pregnancy, 
and one control group that received normal saline on 
the same days. These doses of GBP were the routine 
doses used for the treatment of patients in a clinical 
setting. The GBP powder was obtained from 100 mg 
capsules )Pharma Science, Montreal, Canada(. Dilution 
was carried out by normal saline. Injection dosages for 
mice were calculated according to previous studies.15,16 
Cesarean section was performed under deep anesthesia 
on GD18. Embryos were collected carefully from 
the uteri and external observation was carried out by 
a stereo research microscope )SZX, Olympus, Tokyo, 
Japan(. Fetuses were assessed as either alive or dead 
and exteriorized uterine horns were inspected for fetal 
resorption. Then, each fetus was weighed by a sensitive 
electronic balance. All live fetuses were measured 
and examined externally for gross malformations or 
deviations from normal growth. Fetuses with skeletal 
malformations were chosen for double staining. They 
were kept in 95% ethanol for 3 days and then double 
stained by Alizarin red S-Alcian blue according to a 
slightly modified McLeod18 and Kimmel & Trammel 
technique19 for skeletal malformations. Malformations 
were detected, and photography performed. 
Each fetus was weighed, and data were reported as 
mean ± SD. Tukey test was carried out after ANOVA 
among the control groups and each treated group. With 
regards to the frequency of absorbed fetuses, external 
malformation differences between the control groups 
and each treated group was tested with the χ2 test. The 
unit of frequency analysis was fetuses. All analysis carried 
out with SPSS software )version 11.5(. Differences were 
considered significant at p<0.05. 
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 Table 1 - Cesarean section parameters and external malformations in Balb/c mice fetuses treated with 
gabapentin at doses of 25 & 50 mg/kg )control group received normal saline(. 
Parameters 
Treated groups 
25 mg/kg gabapentin 50 mg/kg gabapentin 
Control group 
(normal saline) 
Litters )n(  10  10  10 
Total number of fetuses )n( 124 118 131 
Live fetuses, n )%( 115 )93(, p=0.67 103 )87(, p=0.45 131 )100( 
Absorbed fetuses, n )%( 9 )7(, p=0.00 15 )13(, p=0.00 0 
Fetal weight, Mean ±SD )gM( 0.98±0.06, p=0.00 0.91±0.05, p=0.00 1.17±0.03 
Fetuses examined )n( 115 103 131 
Brachygnathia, n )%( 12 )10(, p=0.00 15 )14(, p=0.00  0 
Limbs deformities, n )%( 11 )9(, p=0.00 14 )13(, p=0.00  0 
Vertebral deformity, n )%( 5 )4(, p=0.01 10 )9(, p=0.00  0 
Exencephaly, n )%( 3 )2(, p=0.06 4 )4(, p=0.02  0 
Severe malformation, n )%( 2 )2(, p=0.13 3 )3(, p=0.49  0 
  Figure 1 - A fetus with hypognathia )white arrow( from experimental 
group II, treated with 50 mg/kg/day gabapentin. 
 Figure 2 - A fetus with limb deformities from experimental group II, 
treated with 50 mg/kg/day gabapentin. 
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Results. The frequency of total number of fetuses, 
live fetuses, their weights, and resorbed fetuses, in 
experimental groups I and II, and the control group is 
summarized in Table 1. No significant differences were 
observed in mean number of live fetuses among the 
different studied groups. Significant dose-dependent 
fetal resorption was observed, and a dose-dependent 
weight reduction of treated fetuses was also observed 
)Table 1(. Brachygnathia, deformities in vertebral 
column and limbs, exencephaly, and also fetuses with 
severe malformations were observed in experimental 
groups I and II )Table 1(. Brachygnathia was the most 
prominent malformation in both treated groups. Our 
result showed that approximately 10% of fetuses in 
group I and 14% of fetuses in group II had a significantly 
smaller mandible. In these fetuses, the snout was narrow 
and pointed due to the small mandible )Figure 1(. Limb 
anomalies were the second prevalent deformity that was 
observed among the fetuses of the experimental groups. 
These deformities included malrotation and delayed 
development in upper and lower limbs that appeared as 
micromelia )Figure 2(. Nine percent of fetuses in group 
I, and 13% in group II had limbs deformities. The third 
prevalent anomaly was vertebral column deformity, 
which was determined as deviations in normal curvatures. 
Our results showed that 4% of fetuses in group I, and 
9% in group II had this malformation )Table 1(. A 
number of fetuses in experimental groups I )2%( and 
  
Table 2 -	 Skeletal malformations in Balb/c mice fetuses treated with gabapentin at doses of 25 & 50 mg/kg 
)control group received normal saline(. 
Parameters 
Treated groups 
25 mg/kg gabapentin 50 mg/kg gabapentin 
Control group 
(normal saline) 
Litters )n(  10  10  10 
Fetuses examined )n( 115 103 131 
Mandibular hypoplasia, n )%( 12 )10(, p=0.00 15 )14(, p=0.00  0 
Vertebral column deformity, n )%( 5 )3(, p=0.01 10 )9.7(, p=0.00  0 
Calvaria deformities, n )%( 15 )13(, p=0.00 20 )19(, p=0.00  0 
Delayed ossification, n )%( 20 )17(, p=0.00 27 )26(, p=0.00  0 
  Figure 3 - A fetus with exencephaly )white arrow( from experimental 
group II, treated with 50 mg/kg/day gabapentin. 
  Figure 4 - A fetus skeleton with mandibular hypoplasia )black arrow(
from experimental group II, treated with 50 mg/kg/day 
gabapentin, which has been stained with Alizarin red S- 
Alcian blue. 
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Figure 5 - A fetus skeleton with scoliosis from experimental group 
II, treated with 50 mg/kg/day gabapentin, which has been 
stained with Alizarin red S-Alcian blue. 
 Figure 6 - A fetus skeleton with calvaria deformities from experimental 
group II, treated with 50 mg/kg/day gabapentin. 
II )4%( showed exencephaly, and this was significant in 
group II. In these fetuses, the bones of calvaria did not 
develop and the brain was exposed and was in contact 
with the amniotic fluid )Figure 3(. Severe malformations 
were observed in the trunks of fetuses in experimental 
group I )2%( and group 2 )3%(. It was hardly possible 
to determine different parts of these trunks, and the 
trunk was very small and pale. A difference of this 
malformation was statistically significant only between 
experimental group II and the control group )Table 1(. 
Mandibular hypoplasia, malformations of vertebrae, and 
bones of calvaria, and delayed ossification were skeletal 
anomalies observed following Alizarin red S and Alcian 
blue double staining )Table 2(. Significant mandibular 
242 Neurosciences 2009; Vol. 14 )3( 
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hypoplasia was observed in both treated groups )Figure 
4(. Significant vertebrae malformations including 
deformities in normal route of vertebral column such 
as scoliosis were observed in both treated groups )Figure 
5(. As shown in Figure 6, significant defects of calvaria 
were more obvious in frontal and parietal bones, which 
appeared as overlapping and defects in formation 
of these bones )13% in group I, and 19% in group 
II(. Significant delayed ossification was obvious in 
metacarpus and metatarsals bones. Primary ossification 
centers in these bones and phalanges did not appear. 
Density of compact bones of forearm and leg decreased 
and calvaria also showed delayed ossification. 
Discussion. This investigation showed that 
injection of GBP at doses of 25 mg/kg and 50 mg/kg 
doses comparable to doses in patients using GBP, during 
the implantation, neurulation, and organogenesis 
stages can cause reduction of fetus weight, increasing 
fetus resorption, brachygnathia, vertebral column 
deformity, limbs anomalies, exencephaly, severe trunk 
malformations, mandibular hypoplasia, malformations 
of calvaria, and delayed ossification. These findings are 
in contradiction to the observations by Petrere and 
Anderson.12 They studied the teratogenic effects of GBP 
in mice with different doses of 500 up to 3,000 mg/kg 
on gestational days 6-15 and concluded that GBP 
exposure during pregnancy was not associated with an 
increased risk for adverse maternal and fetal events. This 
contradiction might be related to the different mice 
strains that were used in their study. 
In this study, a significant increase in resorbed fetuses 
was observed in the experimental groups as compared 
with the fetuses in the control group. Similar findings 
have been reported by Afshar and Golalipour,15 after 
injection of GBP intraperitoneally in doses of 1400 
mg/day and 1800 mg/day during GD1 to GD 10 in 
pregnant mice. Prakash et al20 injected GBP in doses 
of 1800 mg/day and 3600 mg/day intraperitoneally in 
mid GD )7-12( and late GD )13- 17(, and also reported 
similar results. Also, the mean weight of fetuses in the 
treated groups was significantly less than the control 
group, similar to the findings of Afshar and Golalipour.15 
Furthermore, in Prakash et al’s study,20 which in addition 
to weight, assessed the length of the fetuses, reported that 
crown-rump decreased significantly in the treated groups 
receiving GBP in mid and late GDs in comparison with 
the corresponding control group. In their study, small 
bodies in the experimental groups were observed.20 The 
Neurontin Registry study16 that was performed on 39 
pregnant women who were taking GBP showed that 
gabapentin exposure does not carry an increased risk 
of malformation, fetal loss, low birth weight babies, or 
maternal complications. Brachygnathia was the most 
prevalent observed anomaly in fetuses of experimental 
groups I and II. This finding was also similar to Prakash 
et al’s study.20 In our study, bone double staining showed 
that brachygnathia was due to mandibular hypoplasia 
)Table 2(. Another observed macroscopic malformation 
in the treated groups was limb defects that appeared as 
abnormal growth and malrotation limbs. Such anomalies 
have been reported by Prakash et al,20 and Afshar and 
Golalipoor.15 Therefore, the present study confirms that 
relative GBP exposure can produce limbs anomalies. 
Deformities in vertebrae were another anomaly that 
appeared as abnormal curvatures along the vertebral 
column like scoliosis. Deviation in the vertebral column 
has been reported in a previous study.12 In Prakash et al’s 
study, shortening of the neck has been reported.20 Severe 
trunk malformations were the other observed anomaly. 
Very small bodies, albino, and abundant malformations 
in different parts of the trunk were characteristics of 
these malformed fetuses. This malformation has not 
been reported in previous studies of other AED’s. 
However, despite the low frequency of this anomaly, 
this is a significant observation that needs to be further 
investigated. The latest gross malformation observed 
was exencephaly, and was found in both treated groups, 
only the difference between experimental group II and 
the control group was significant. 
Anomalies of calvaria were the most common 
skeletal anomalies observed in this study. Defects of the 
calvaria were more obvious in the frontal and parietal 
bones, and appeared as overlapping defects in the 
formation of these bones. This finding has not been 
reported in previous studies. In macroscopic studies 
of the fetal skeleton, delayed ossification was observed 
and appeared predominantly in the metacarpus and 
metatarsal bones. Long bones in the forearm and leg 
also showed a decrease in the density of compact bone 
tissue. Primary ossification centers did not appear in 
these bones and phalanges. The calvaria also showed 
delayed ossification. In a study, in which GBP has been 
administered orally in doses of 1000-3000 mg/day 
during the organogenesis period, delayed ossification 
was observed in calvaria, vertebrae, humorous, and 
forearm bones, similar to our findings.10 
The exact mechanism or mechanisms of the 
teratogenic effects of GBP are not yet clear, and need 
further investigation. However, alterations in GABA 
neurotransmitter concentration may be an important 
factor in probable teratogenic mechanisms.21 As GBP 
has structural similarities with GABA, )in fact, it is 
an analog of GABA(, hence, it is possible that GBP’s 
teratogenic effects, especially producing NTD, may be 
related to changes in GABA concentration or influence 
on GABA metabolism. 
  
 
 
 
 
 
 
       
In conclusion, our study was limited by the animal 
model and the 2 doses of GBP used. According to our 
findings, GBP may have potential teratogenic effects 
similar to other AEDs, however with less intensity 
than other drugs. Therefore, it is suggested that great 
caution be used when prescribing this drug during the 
early stages of pregnancy. Furthermore, more detailed 
studies, by different routes of administration and more 
emphasis on mechanistic studies need to be performed. 
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